Skip to main content

Table 2 Provision of proven efficacious therapies in patients with CAD, multi-centre studies since 1995

From: A randomized trial to assess the impact of opinion leader endorsed evidence summaries on the use of secondary prevention strategies in patients with coronary artery disease: the ESP-CAD trial protocol [NCT00175240]

Setting (ref) Sample Size Statin Use ACE InhibitorUse Beta-blockerUse Antiplatelet Use Current Smokers % with cholesterol at or below target*
Audits from General Practices:
Canada (42) 4315 38% NR NR 53% 25% 14%
Canada (43) NR NR NR NR 54% NR NR
USA (46) 11 745 NR NR 21% NR NR NR
UK (41) 1921 NR 10% 32% 63% 18% 17%
UK (44) 24 431 16% 13% 22% 50% 24% 56%
Canada (49) 3721 100% NR NR NR 17% 73%
International REACH Registry (50) 40 258 76% 51% 63% 86% 13% NR
Audits in patients discharged after acute myocardial infarction or coronary artery bypass surgery:
USA (39) 201 752 NR 30% 34% 83% NR NR
USA (37) 1710 12% NR 44% 53% NR NR
USA (38) 622 37% NR 23% 46% 25% 15%
USA (45) 190 015 NR 31% NR NR NR NR
USA (47) 25 000 NR NR NR 81% NR NR
Europe (40) 3379 58% 43% 66% 84% 21% 41%
Ontario(48) 9667 40% 65% 68% NR NR NR
Quebec(48) 4790 43% 57% 68% NR NR NR
British Columbia(48) 2570 42% 58% 61% NR NR NR
Nova Scotia(48) 761 36% 58% 83% NR NR NR
Alberta (APPROACH patients)** 5104 34% 39% 61% 81% NR NR
  1. Note that while the general practice audits represent cross-sectional data at varying times after the diagnosis of CAD, the audits in patients discharged after acute MI generally represent prescribing data between 90 days and 120 days after MI.
  2. * Target cholesterol defined as LDL cholesterol ≤ 2.6 mmol/L or total cholesterol ≤ 5.0 mmol/L.
  3. ** Medications in use at the time of the cardiac catheterization (no data available on prescriptions in follow-up). [Colleen Norris, personal communication, August 2003]